Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “neutral” rating reissued by Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell in a research report issued to clients and investors on Tuesday, AR Network reports. They presently have a $108.00 target price on the biotechnology company’s stock, down from their prior target price of $215.00. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell’s price target points to a potential upside of 23.82% from the company’s previous close.
A number of other equities research analysts have also recently issued reports on SRPT. Needham & Company LLC decreased their price target on shares of Sarepta Therapeutics from $182.00 to $166.00 and set a “buy” rating for the company in a report on Friday, January 8th. Piper Sandler upped their price target on shares of Sarepta Therapeutics from $200.00 to $240.00 and gave the company an “overweight” rating in a report on Monday, January 4th. BidaskClub lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 6th. Cantor Fitzgerald cut their price objective on shares of Sarepta Therapeutics from $217.00 to $128.00 and set an “overweight” rating for the company in a research report on Friday, January 8th. Finally, JPMorgan Chase & Co. lowered shares of Sarepta Therapeutics from an “overweight” rating to an “underweight” rating and set a $96.00 price objective for the company. in a research report on Friday, January 8th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and sixteen have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $160.38.
SRPT stock opened at $87.22 on Tuesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 6.93 and a quick ratio of 6.42. Sarepta Therapeutics has a 52-week low of $78.06 and a 52-week high of $181.83. The company has a 50-day moving average of $153.98 and a two-hundred day moving average of $148.77. The stock has a market capitalization of $6.88 billion, a price-to-earnings ratio of -12.42 and a beta of 1.82.
In other Sarepta Therapeutics news, insider Joseph Bratica sold 1,115 shares of the firm’s stock in a transaction that occurred on Friday, December 11th. The shares were sold at an average price of $165.00, for a total value of $183,975.00. Following the transaction, the insider now directly owns 9,255 shares of the company’s stock, valued at $1,527,075. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 5.90% of the stock is currently owned by company insiders.
A number of hedge funds have recently made changes to their positions in SRPT. Pathstone Family Office LLC boosted its stake in Sarepta Therapeutics by 270.9% in the third quarter. Pathstone Family Office LLC now owns 204 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 149 shares during the last quarter. Private Advisor Group LLC bought a new position in Sarepta Therapeutics in the second quarter valued at approximately $30,000. Patriot Financial Group Insurance Agency LLC boosted its stake in Sarepta Therapeutics by 84.7% in the third quarter. Patriot Financial Group Insurance Agency LLC now owns 436 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 200 shares during the last quarter. HM Payson & Co. bought a new position in Sarepta Therapeutics in the third quarter valued at approximately $76,000. Finally, Pacer Advisors Inc. acquired a new stake in Sarepta Therapeutics in the third quarter worth $93,000. 92.70% of the stock is currently owned by hedge funds and other institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.
Further Reading: Why is the price-sales ratio important?
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.